Celltrion said Monday it continues to see solid prescription growth across Asian markets, with several of its key biosimilar products capturing leading market shares.
Its flagship autoimmune disease treatment Remsima has established a dominant presence in multiple markets.
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.